These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 26616466)

  • 21. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
    Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
    J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
    Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
    Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
    BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
    Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
    Temmink OH; Emura T; de Bruin M; Fukushima M; Peters GJ
    Cancer Sci; 2007 Jun; 98(6):779-89. PubMed ID: 17441963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
    Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
    Bendell JC; Rosen LS; Mayer RJ; Goldman JW; Infante JR; Benedetti F; Lin D; Mizuguchi H; Zergebel C; Patel MR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):925-32. PubMed ID: 26370544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
    Nukatsuka M; Nakagawa F; Saito H; Sakata M; Uchida J; Takechi T
    Anticancer Res; 2015 Mar; 35(3):1437-45. PubMed ID: 25750295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
    Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
    Petrelli F; Barni S; Bertocchi P; Zaniboni A
    BMC Cancer; 2016 Jul; 16():386. PubMed ID: 27377645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
    Kimura M; Usami E; Iwai M; Teramachi H; Yoshimura T
    Pharmazie; 2017 Jan; 72(1):49-52. PubMed ID: 29441897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
    Temmink OH; Prins HJ; van Gelderop E; Peters GJ
    Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated safety summary for trifluridine/tipiracil (TAS-102).
    Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
    Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In brief: trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2016 Jun; 58(1496):e77. PubMed ID: 27249100
    [No Abstract]   [Full Text] [Related]  

  • 39. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Bando H; Doi T; Muro K; Yasui H; Nishina T; Yamaguchi K; Takahashi S; Nomura S; Kuno H; Shitara K; Sato A; Ohtsu A
    Eur J Cancer; 2016 Jul; 62():46-53. PubMed ID: 27208903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
    Scagliotti G; Nishio M; Satouchi M; Valmadre G; Niho S; Galetta D; Cortinovis D; Benedetti F; Yoshihara E; Makris L; Inoue A; Kubota K
    Lung Cancer; 2016 Oct; 100():20-23. PubMed ID: 27597276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.